Femoral Insufficiency Fractures Associated with Prolonged Bisphosphonate Therapy

被引:65
作者
Isaacs, Joseph D. [1 ,2 ]
Shidiak, Louis [1 ,2 ]
Harris, Ian A. [3 ]
Szomor, Zoltan L. [2 ]
机构
[1] Univ New S Wales, Dept Orthopaed Surg, St George Hosp, Sydney, NSW 2217, Australia
[2] St George & Sutherland Hosp Orthopaed Dept, Sydney, NSW, Australia
[3] Univ New S Wales, Dept Orthopaed Surg, SW Sydney Clin Sch, Liverpool Hosp, Liverpool, NSW 2170, Australia
关键词
SUPPRESSED BONE TURNOVER; LONG-TERM ALENDRONATE; POSTMENOPAUSAL OSTEOPOROTIC WOMEN; INTERVENTION-TRIAL; MICRODAMAGE ACCUMULATION; BIOMECHANICAL PROPERTIES; RANDOMIZED-TRIAL; ORAL ALENDRONATE; MECHANICAL-PROPERTIES; VERTEBRAL FRACTURES;
D O I
10.1007/s11999-010-1535-x
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background Emerging evidence has linked the long-term use of bisphosphonates with femoral insufficiency fractures. It has been suggested that the prolonged effect on bone remodeling leads to the accumulation of microfractures and weakening of bone. Questions/purposes We investigated the association between bisphosphonate use and femoral insufficiency fractures. Methods We evaluated 100 patients with low-energy femoral shaft fractures before and after bisphosphonates became available for use. Twenty-one consecutive patients who presented between January 1995 and February 1997 were compared with 79 consecutive patients who presented between January 2007 and February 2009. The radiographs of all 100 patients were examined for evidence of preexisting insufficiency fractures. We identified insufficiency fractures by a transverse fracture line on the tension side of the femur with lateral cortical thickening immediately adjacent to the fracture. Relevant details from the history were recorded. Results Forty-one patients had an underlying femoral insufficiency fracture, all of whom had been receiving bisphosphonate therapy. Among the 21 patients with low-energy femoral fractures before the availability of bisphosphonates, none had insufficiency fractures. Of the 41 patients with insufficiency fractures, 29 (71%) had prodromal pain and 18 (44%) had bilateral insufficiency fractures. Bisphosphonate use was associated (odds ratio greater than 1000) with insufficiency fracture. The mean duration of bisphosphonate use in patients with insufficiency fractures was longer than in patients without fractures (7.1 versus 3.2 years). Conclusion Long-term bisphosphonate use is associated with insufficiency fractures of the femoral shaft, which commonly present with prodromal thigh pain and may be bilateral. These fractures were not seen before bisphosphonates became available for use.
引用
收藏
页码:3384 / 3392
页数:9
相关论文
共 68 条
[41]   Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib [J].
Mashiba, T ;
Hirano, T ;
Turner, CH ;
Forwood, MR ;
Johnston, CC ;
Burr, DB .
JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (04) :613-620
[42]   Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles [J].
Mashiba, T ;
Turner, CH ;
Hirano, T ;
Forwood, MR ;
Johnston, CC ;
Burr, DB .
BONE, 2001, 28 (05) :524-531
[43]   Effect of risedronate on the risk of hip fracture in elderly women [J].
McClung, MR ;
Geusens, P ;
Miller, PD ;
Zippel, H ;
Bensen, WG ;
Roux, C ;
Adami, S ;
Fogelman, I ;
Diamond, T ;
Eastell, R ;
Meunier, PJ ;
Reginster, JY ;
Wasnich, RD ;
Greenwald, M ;
Kaufman, J ;
Chestnut, CH .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (05) :333-340
[44]   Bisphosphonate-associated femoral fracture: implications for management in patients with malignancies [J].
Napoli, N. ;
Novack, D. ;
Armamento-Villareal, R. .
OSTEOPOROSIS INTERNATIONAL, 2010, 21 (04) :705-708
[45]   Low-energy femoral shaft fractures associated with alendronate use [J].
Neviaser, Andrew S. ;
Lane, Joseph M. ;
Lenart, Brett A. ;
Edobor-Osula, Folorunsho ;
Lorich, Dean G. .
JOURNAL OF ORTHOPAEDIC TRAUMA, 2008, 22 (05) :346-350
[46]   Severely suppressed bone turnover: A potential complication of alendronate therapy [J].
Odvina, CV ;
Zerwekh, JE ;
Rao, DS ;
Maalouf, N ;
Gottschalk, FA ;
Pak, CYC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (03) :1294-1301
[47]   Alendronate for the treatment of osteoporosis in men [J].
Orwoll, E ;
Ettinger, M ;
Weiss, S ;
Miller, P ;
Kendler, D ;
Graham, J ;
Adami, S ;
Weber, K ;
Lorenc, R ;
Pietschmann, P ;
Vandormael, K ;
Lombardi, A ;
Adachi, JD ;
Bell, N ;
Body, JJ ;
Castro, A ;
Daifotis, A ;
Felsenberg, D ;
Gilchrist, N ;
Hoffman, A ;
Maricic, M ;
Rizzoli, R ;
Silverman, S ;
Valeriano, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (09) :604-610
[48]   Editorial: Long-term safety of bisphosphonates [J].
Ott, SM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (03) :1897-1899
[49]  
OTT SM, ORTHOPEDICS, V33, P468
[50]   TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH SLOW-RELEASE SODIUM-FLUORIDE [J].
PAK, CYC ;
SAKHAEE, K ;
ADAMSHUET, B ;
PIZIAK, V ;
PETERSON, RD ;
POINDEXTER, JR .
ANNALS OF INTERNAL MEDICINE, 1995, 123 (06) :401-408